202 related articles for article (PubMed ID: 26385244)
1. [Combined chemohormonal therapy for metastatic hormone-sensitive prostate cancer : Effectiveness and update as a joint statement by the Study Group on Oncology (AKO) and the Working Group on Urological Oncology (AUO)].
Ohlmann CH; Gschwend J; Miller K;
Urologe A; 2015 Nov; 54(11):1606-8. PubMed ID: 26385244
[No Abstract] [Full Text] [Related]
2. [Androgen deprivation plus abiraterone/prednisone in metastatic hormone-sensitive prostate cancer : Joint statement by the Study Group on Oncology (AKO) and the Working Group on Urological Oncology (AUO)].
Ohlmann CH; Miller K; Gschwend J
Urologe A; 2017 Sep; 56(9):1185-1186. PubMed ID: 28733874
[No Abstract] [Full Text] [Related]
3. [Drug therapy of hormone-sensitive metastatic prostate cancer : Consensus paper of the AKO/AUO].
Ohlmann CH; Gschwend J; Miller K
Urologe A; 2016 Sep; 55(9):1164-72. PubMed ID: 27431813
[TBL] [Abstract][Full Text] [Related]
4. Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer.
Ponholzer A; Loidl W; Bektic J; Dorfinger K; Hruby S; Jeschke K; Kramer G; Krause S; Ludvik G; Remzi M; Roider M; Stoiber F
Wien Klin Wochenschr; 2016 Feb; 128(3-4):156-63. PubMed ID: 26831188
[TBL] [Abstract][Full Text] [Related]
5. [Specialist uro-oncological rehabilitation after treatment for prostate cancer--update 2015. Position statement of the working group on "rehabilitation of urological and nephrological diseases" of the German Society of Urology with respect to current S3 guidelines].
Müller G; Otto U; Vahlensieck W; Zermann DH
Urologe A; 2015 Aug; 54(8):1108-14. PubMed ID: 26246209
[TBL] [Abstract][Full Text] [Related]
6. NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection.
Carroll PH; Mohler JL
J Natl Compr Canc Netw; 2018 May; 16(5S):620-623. PubMed ID: 29784740
[TBL] [Abstract][Full Text] [Related]
7. Appendix 1: Cancer of the Prostate: eUpdate published online 28 September 2017 (http://www.esmo.org/Guidelines/Genitourinary-Cancers/Cancer-of-the-Prostate).
ESMO Guidelines Committee
Ann Oncol; 2018 Oct; 29(Suppl 4):iv256. PubMed ID: 30285212
[No Abstract] [Full Text] [Related]
8. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.
Lowrance WT; Breau RH; Chou R; Chapin BF; Crispino T; Dreicer R; Jarrard DF; Kibel AS; Morgan TM; Morgans AK; Oh WK; Resnick MJ; Zietman AL; Cookson MS
J Urol; 2021 Jan; 205(1):14-21. PubMed ID: 32960679
[TBL] [Abstract][Full Text] [Related]
9. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
[TBL] [Abstract][Full Text] [Related]
10. [Second line AUO (Working Group Urological Oncology) study AB 35/09 on metastasized urothelial carcinoma. Phase II study with RAD001 in combination with paclitaxel for patients with metastasized urothelial carcinoma of the urinary bladder after failure of platinum-based chemotherapy (CRAD001)].
Rexer H
Urologe A; 2011 Nov; 50(11):1464-5. PubMed ID: 22042448
[No Abstract] [Full Text] [Related]
11. A re-assessment of the role of combined androgen blockade for advanced prostate cancer.
Klotz L; Schellhammer P; Carroll K
BJU Int; 2004 Jun; 93(9):1177-82. PubMed ID: 15180600
[No Abstract] [Full Text] [Related]
12. [Advanced Prostate Cancer Consensus Conference (APCCC) 2015 in St. Gallen : Critical review of the recommendations on diagnosis and therapy of metastatic prostate cancer by a German expert panel].
Thomas C; Bögemann M; König F; Machtens S; Schostak M; Steuber T; Heidenreich A
Urologe A; 2016 Jun; 55(6):772-82. PubMed ID: 26820660
[TBL] [Abstract][Full Text] [Related]
13. ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer.
Sweeney CJ
Clin Adv Hematol Oncol; 2006 Aug; 4(8):588-90. PubMed ID: 17111557
[No Abstract] [Full Text] [Related]
14. [S3 guideline for bladder cancer : Claim and reality - a critical commentary from the guideline coordinators].
Retz M; Maisch P; Gschwend JE
Urologe A; 2016 Sep; 55(9):1188-91. PubMed ID: 27581238
[No Abstract] [Full Text] [Related]
15. What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations.
Yu EY; Gillessen S; Mottet N
Eur Urol Focus; 2019 Mar; 5(2):162-164. PubMed ID: 30287277
[TBL] [Abstract][Full Text] [Related]
16. [Quality in urology].
Miller K
Urologe A; 2016 Sep; 55(9):1163. PubMed ID: 27514388
[No Abstract] [Full Text] [Related]
17. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.
Lowrance WT; Breau RH; Chou R; Chapin BF; Crispino T; Dreicer R; Jarrard DF; Kibel AS; Morgan TM; Morgans AK; Oh WK; Resnick MJ; Zietman AL; Cookson MS
J Urol; 2021 Jan; 205(1):22-29. PubMed ID: 32960678
[TBL] [Abstract][Full Text] [Related]
18. Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer.
Lin CJ; Hsieh RK; Lim KH; Chen HH; Cheng YC; Wu CJ
South Med J; 2007 Sep; 100(9):916-7. PubMed ID: 17902299
[No Abstract] [Full Text] [Related]
19. Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Taneja SS
J Urol; 2016 Jan; 195(1):94. PubMed ID: 26699961
[No Abstract] [Full Text] [Related]
20. [The study landscape for prostate cancer].
Miller K
Urologe A; 2005 Dec; 44(12):1431-4. PubMed ID: 16292461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
